Fairvalue-Calculator Fairvalue-Calculator

Green Thumb Industries Inc (GTBIF) Fair Value & Analysis

Healthcare · US · Market cap $1.7B

Price$7.20
Fair Value$12.87
Upside+78.8%
Quality95/100
Evidence: High Range $9.66 – $16.09

Analysis

Green Thumb Industries Inc (GTBIF) currently trades at $7.20, while our model-based Fair Value estimate is $12.87 — implying the stock looks roughly 78.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, tinctures, edibles, topicals, capsules, tinctures, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, RYM, and RHYTHM brands. It distributes its products to third-party licensed retail customers; and sells finished products to third-party licensed retail cannabis stores. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.